StreetInsider.com News Articles

Climb Bio shares phase 2 data for budoprutug in kidney disease

Sat, 24 Oct 2026 19:30:14 -0400

Climb Bio, Inc. (Nasdaq: CLYM) presented initial data from its PrisMN Phase 2 trial of budoprutug, an anti-CD19 monoclonal antibody, in patients with primary membranous nephropathy (pMN) at the American Society of Nephrology Kidney Week 2026 in Denver, Colorado.

The ongoing dose-escalation trial is evaluating budoprutug at 200 mg, 600 mg, and 1,000 mg in patients with moderate to severe pMN. At Week 12, patients in the 200 mg cohort showed a mean 70% reduction in PLA2R antibody levels, with five of 13 patients (38%) achieving immunologic remission. Early data from the 600 mg cohort showed mean peripheral CD20+ B-cell suppression

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Sat, 24 Oct 2026 19:30:00 -0400

Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027

200 mg and 600 mg doses have been generally well-tolerated

Separate MCD case study described three-year steroid-free remission following budoprutug treatment, supporting further investigation

WELLESLEY HILLS, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced new clinical data for budoprutug, its

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Sat, 24 Oct 2026 19:30:00 -0400

200 mg and 600 mg doses have been generally well-tolerated

Separate MCD case study described three-year steroid-free remission following budoprutug treatment, supporting further investigation

Form 8-K Climb Bio, Inc. For: Oct 23

Fri, 23 Oct 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20261023/27228700.html

Climb Bio and Mabworks report Phase 1 data for IgAN antibody CLYM116

Fri, 23 Oct 2026 16:04:39 -0400

Climb Bio, Inc. (Nasdaq: CLYM) and Beijing Mabworks Biotech Co., Ltd. presented Phase 1 data from two healthy volunteer studies of CLYM116/MIL116, an anti-APRIL monoclonal antibody in development for IgA nephropathy (IgAN), at the American Society of Nephrology Kidney Week 2026 in Denver, Colorado.

The data came from two randomized, double-blind, placebo-controlled, ascending-dose studies conducted in Australia and China, enrolling 46 and 42 participants respectively. Both studies evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous CLYM116/MIL116.

Key findings included greater than 90% free APRIL suppression sustained through 12 weeks following a single subcutaneous dose of 480 mg or higher. Following a

Climb Bio and Mabworks report Phase 1 data for IgAN antibody CLYM116

Fri, 23 Oct 2026 16:04:39 -0400

Key findings included greater than 90% free APRIL suppression sustained through 12 weeks following a single subcutaneous dose of 480 mg or higher. Following a

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Fri, 23 Oct 2026 16:01:00 -0400

>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval

~70% reduction in Gd-IgA1 at 12 weeks

~33-day half-life

NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in the first half of 2027

Global Phase 3 trial expected to initiate in 2027

WELLESLEY HILLS, Mass. and BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM, “Climb Bio”) and Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), today announced additional Phase 1 data in healthy volunteers for CLYM116/MIL116, an anti-APRIL monoclonal antibody (mAb), in

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Fri, 23 Oct 2026 16:01:00 -0400

>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval

~70% reduction in Gd-IgA1 at 12 weeks

~33-day half-life

NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in the first half of 2027

Global Phase 3 trial expected to initiate in 2027

A 40% drop in this stock is a buying opportunity: B. Riley

Fri, 23 Oct 2026 09:00:00 -0400

A roughly 40% pullback from its 52-week high makes for an enhanced entry point in one clinical-stage biotech stock heading into the American Society of Nephrology's Kidney Week meeting, one analyst says.

B. Riley Securities said analyst Mayank Mamtani reiterated a Buy rating and $30 price target on Climb Bio (NASDAQ: CLYM), saying that "modest investor expectations" for both of the company's key programs, budoprutug and CLYM116, "represent potentially significant room for upside surprise."

Mamtani called Saturday's Phase 2 PrisMN oral presentation of budoprutug in primary membranous nephropathy "the most stock-relevant of CLYM's four presentations."

He expects 12-week B-cell and anti-PLA2R

A 40% drop in this stock is a buying opportunity: B. Riley

Fri, 23 Oct 2026 09:00:00 -0400

Mamtani called Saturday's Phase 2 PrisMN oral presentation of budoprutug in primary membranous nephropathy "the most stock-relevant of CLYM's four presentations."

He expects 12-week B-cell and anti-PLA2R

Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline

Tue, 20 Oct 2026 11:04:00 -0400

Investing.com -- Climb Bio Inc (NASDAQ:CLYM) shares rallied over 10% in Tuesday morning trading following a bullish initiation from Deutsche Bank, which highlighted the clinical-stage biotech's autoimmune pipeline and attractive entry valuation. The firm assigned a Buy rating and a $28 price target, pointing to the company's lead asset as a key driver for future growth.

Deutsche Bank analyst David Hoang emphasized that Climb Bio's current valuation offers an appealing entry point after a month-long pullback, which he attributed primarily to broader sector-wide pressure rather than company-specific fundamentals. The market is underestimating the commercial potential Climb

Deutsche Bank Starts Climb Bio (CLYM) at Buy, 'Compelling Immunology Pipeline Led by IgAN'

Tue, 20 Oct 2026 07:14:30 -0400

(Updated - October 20, 2026 7:14 AM EDT)

Deutsche Bank analyst David Hoang initiates coverage on Climb Bio (NASDAQ: CLYM) with a Buy rating and a price target of $28.00.

The analyst comments "CLYM is a clinical-stage biotech company with two promising assets in development for autoimmune diseases. CLYM116 (licensed from Mabworks) is a potential best-in-class APRIL inhibitor for IgA nephropathy (IgAN). Budoprutug (via acquisition of Tenet) is a potential best-in-class, and in some cases, first-in-class, anti-CD19 therapy for several B cell-mediated disorders (pMN, ITP, SLE). CLYM’s current valuation provides an attractive entry point following a month-long pullback, which we believe was

Deutsche Bank Starts Climb Bio (CLYM) at Buy, 'Compelling Immunology Pipeline Led by IgAN'

Tue, 20 Oct 2026 07:14:30 -0400

(Updated - October 20, 2026 7:14 AM EDT)

Deutsche Bank analyst David Hoang initiates coverage on Climb Bio (NASDAQ: CLYM) with a Buy rating and a price target of $28.00.

Deutsche Bank Starts Climb Bio (CLYM) at Buy, 'Compelling Immunology Pipeline Led by IgAN'

Tue, 20 Oct 2026 07:14:30 -0400

(Updated - October 20, 2026 7:14 AM EDT)

Deutsche Bank analyst David Hoang initiates coverage on Climb Bio (NASDAQ: CLYM) with a Buy rating and a price target of $28.00.

Deutsche Bank Starts Climb Bio (CLYM) at Buy, 'Compelling Immunology Pipeline Led by IgAN'

Tue, 20 Oct 2026 07:14:30 -0400

(Updated - October 20, 2026 7:14 AM EDT)

Deutsche Bank analyst David Hoang initiates coverage on Climb Bio (NASDAQ: CLYM) with a Buy rating and a price target of $28.00.

H.C. Wainwright Reiterates Buy Rating on Climb Bio (CLYM)

Mon, 12 Oct 2026 06:54:35 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $30.00 price target on Climb Bio (NASDAQ: CLYM).

The analyst commented: "We draw investors' attention to the fact that Climb Bio is slated to present new clinical data for its CLYM116 and budoprutug programs across three immune-mediated kidney diseases at the American Society of Nephrology (ASN) Kidney Week 2026, which will be held in Denver, CO from October 21-25, 2026. On October 22, 2026, a poster entitled "CLYM116, a Novel "Sweeper" Anti-A PRoliferation-Inducing Ligand Monoclonal Antibody in Development for IgAN: Phase 1 Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) Results in

Raymond James Reiterates Strong Buy Rating on Climb Bio (CLYM)

Mon, 05 Oct 2026 05:17:24 -0400

Raymond James analyst Christopher Raymond reiterated a Strong Buy rating and $34.00 price target on Climb Bio (NASDAQ: CLYM).

The analyst comments "Remain Strong Buy rated on CLYM shares following the release of the abstract for initial P2 budoprutug (budo) data in primary membranous nephropathy (pMN) to be presented at ASN Kidney Week on October 24. Recall CLYM has previously guided that this data release would likely only encompass safety and short-term biomarker data for the low dose (200 mg) cohort. As of the abstract’s data cut-off, 11 patients have been enrolled in this cohort, with 5 patients having been administered

Climb Bio to present kidney disease data at ASN 2026 conference

Fri, 02 Oct 2026 09:30:18 -0400

Climb Bio, Inc. (Nasdaq: CLYM) announced it will present clinical data for its CLYM116 and budoprutug programs at the American Society of Nephrology Kidney Week 2026, scheduled for October 21–25 in Denver, Colorado.

The company will deliver four presentations covering three immune-mediated kidney diseases. Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy has been selected for an oral presentation on October 24.

Two poster presentations on CLYM116, an anti-APRIL monoclonal antibody in development for IgA nephropathy, will share Phase 1 safety, tolerability, pharmacokinetics, and pharmacodynamics results from healthy volunteer studies. These posters are scheduled for

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

Fri, 02 Oct 2026 09:30:00 -0400

Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation

Presentations on CLYM116 and budoprutug programs highlight advancements across the portfolio

WELLESLEY HILLS, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for its CLYM116 and budoprutug programs across three immune-mediated kidney diseases at the American Society of Nephrology (ASN) Kidney Week 2026, which will be held in Denver, Colorado

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

Fri, 02 Oct 2026 09:30:00 -0400

Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation

Presentations on CLYM116 and budoprutug programs highlight advancements across the portfolio

Raymond James Updates Healthcare Top Picks for October

Thu, 01 Oct 2026 16:00:03 -0400

Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeutics, Tyra Biosciences, and Oscar Health.

1. Xencor Inc. (XNCR)

Raymond James added Xencor to its top picks list, replacing Relay Therapeutics. The firm anticipates significant interest in Xencor's dataset at ESMO at the end of October. Raymond James sees near-term upside to shares on a positive readout and clear path to pivotal development for

Raymond James Updates Healthcare Top Picks for October

Thu, 01 Oct 2026 16:00:03 -0400

1. Xencor Inc. (XNCR)

Raymond James Updates Healthcare Top Picks for October

Thu, 01 Oct 2026 16:00:03 -0400

1. Xencor Inc. (XNCR)

Form 4 Climb Bio, Inc. For: Sep 28 Filed by: RA Capital Nexus Fund, L.P.

Wed, 30 Sep 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260930/27129272.html

Raymond James Adjusts Analyst Current Favorites List

Wed, 23 Sep 2026 06:31:22 -0400

Raymond James Adjusts Analyst Current Favorites List

ADDS: Climb Bio (NASDAQ: CLYM)
REMOVES: Tyra Biosciences (NASDAQ: TYRA)

The analyst comments "Climb Bio, Inc. (CLYM) is our Analyst Current Favorite given what we think is an increasingly derisked setup for both of CLYM’s lead assets – CLYM116 and budoprutug. For anti-APRIL antibody CLYM116, recent Phase 1 data demonstrated the ability to achieve strong levels of IgA reduction with a plausible every 3-month dosing scheme, which could lead to a best-in-class profile in this expanding multi-billion dollar market. CLYM anticipates sharing initial data from a Phase 2 study next year, which should solidify CLYM116’s efficacy